<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/css/uswds.min.css">
    <link rel="stylesheet" href="/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/html/parts/21CFR522.html">Part 522
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 522.246  Butorphanol.
                            </h3>
                            <p class="depth1"><em>(a)</em> Specifications. Each milliliter of solution contains butorphanol (as

butorphanol tartrate) in the following amounts:</p><p class="depth2"><em>(1)</em> 0.5 milligrams (mg);</p><p class="depth2"><em>(2)</em> 2 mg; or</p><p class="depth2"><em>(3)</em> 10 mg</p><p class="depth1"><em>(b)</em> Sponsors. See sponsors in Sec. 510.600(c) of this chapter as follows:</p><p class="depth2"><em>(1)</em> No. 054771 for use of the product described in paragraph (a)(1) as in paragraph (d)(1) of this section; for use of the product described in paragraph (a)(2) as in paragraph (d)(2) of this section; and for use of the product described in paragraph (a)(3) as in paragraph (d)(3) of this section.</p><p class="depth2"><em>(2)</em> No. 000859 for use of the product described in paragraph (a)(2) as in paragraph (d)(2) of this section.</p><p class="depth2"><em>(3)</em> Nos. 000061, 000859, and 059399 for use of the product described in paragraph (a)(3) as in paragraph (d)(3) of this section.</p><p class="depth1"><em>(c)</em> Special considerations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p><p class="depth1"><em>(d)</em> Conditions of use--(1) Dogs--(i) Amount. Administer 0.025 mg per pound of body weight by subcutaneous injection at intervals of 6 to 12 hours, as required. If necessary, increase dose to a maximum of 0.05 mg per pound of body weight. Treatment should not normally be required for longer than 7 days.</p><p class="depth2"><em>(1)</em> Dogs--(i) Amount. Administer 0.025 mg per pound of body weight by subcutaneous injection at intervals of 6 to 12 hours, as required. If necessary, increase dose to a maximum of 0.05 mg per pound of body weight. Treatment should not normally be required for longer than 7 days.</p><p class="depth3"><em>(i)</em> Amount. Administer 0.025 mg per pound of body weight by subcutaneous injection at intervals of 6 to 12 hours, as required. If necessary, increase dose to a maximum of 0.05 mg per pound of body weight. Treatment should not normally be required for longer than 7 days.</p><p class="depth3"><em>(ii)</em> Indications for use. For the relief of chronic nonproductive cough associated with tracheo-bronchitis, tracheitis, tonsillitis, laryngitis, and pharyngitis associated with inflammatory conditions of the upper respiratory tract.</p><p class="depth2"><em>(2)</em> Cats--(i) Amount. Administer 0.2 mg per pound of body weight by subcutaneous injection. Dose may be repeated up to 4 times per day. Do not treat for more than 2 days.</p><p class="depth3"><em>(i)</em> Amount. Administer 0.2 mg per pound of body weight by subcutaneous injection. Dose may be repeated up to 4 times per day. Do not treat for more than 2 days.</p><p class="depth3"><em>(ii)</em> Indications for use. For the relief of pain in cats caused by major or minor trauma, or pain associated with surgical procedures.</p><p class="depth2"><em>(3)</em> Horses--(i) Amount. Administer 0.05 mg per pound of body weight by intravenous injection. Dose may be repeated within 3 to 4 hours. Treatment should not exceed 48 hours.</p><p class="depth3"><em>(i)</em> Amount. Administer 0.05 mg per pound of body weight by intravenous injection. Dose may be repeated within 3 to 4 hours. Treatment should not exceed 48 hours.</p><p class="depth3"><em>(ii)</em> Indications for use. For the relief of pain associated with colic and postpartum pain in adult horses and yearlings.</p><p class="depth3"><em>(iii)</em> Limitations. Do not use in horses intended for human consumption.
[72 FR 27957, May 18, 2007, as amended at 73 FR 31358, June 2, 2008; 74 FR 61516, Nov. 25, 2009; 75 FR 22524, Apr. 29, 2010; 77 FR 60302, Oct. 3, 2012; 78 FR 17597, Mar. 22, 2013; 79 FR 16184, Mar. 25, 2014; 79 FR 74020, Dec. 15, 2014; 80 FR 13229, Mar. 13, 2015]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
